NL300999I2 - macimorelin - Google Patents

macimorelin Download PDF

Info

Publication number
NL300999I2
NL300999I2 NL300999C NL300999C NL300999I2 NL 300999 I2 NL300999 I2 NL 300999I2 NL 300999 C NL300999 C NL 300999C NL 300999 C NL300999 C NL 300999C NL 300999 I2 NL300999 I2 NL 300999I2
Authority
NL
Netherlands
Prior art keywords
macimorelin
Prior art date
Application number
NL300999C
Other languages
English (en)
Other versions
NL300999I1 (nl
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of NL300999I1 publication Critical patent/NL300999I1/nl
Publication of NL300999I2 publication Critical patent/NL300999I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Surgery (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
NL300999C 2000-06-13 2019-07-05 macimorelin NL300999I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21132600P 2000-06-13 2000-06-13
US23492800P 2000-09-26 2000-09-26
PCT/EP2001/006717 WO2001096300A1 (en) 2000-06-13 2001-06-13 Growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NL300999I1 NL300999I1 (nl) 2019-07-17
NL300999I2 true NL300999I2 (nl) 2019-08-28

Family

ID=26906052

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300999C NL300999I2 (nl) 2000-06-13 2019-07-05 macimorelin

Country Status (30)

Country Link
US (2) US6861409B2 (nl)
EP (1) EP1289951B1 (nl)
JP (2) JP3522265B2 (nl)
KR (1) KR100825109B1 (nl)
CN (1) CN1232507C (nl)
AR (1) AR029941A1 (nl)
AT (3) ATE302181T1 (nl)
AU (2) AU2001266066B2 (nl)
BG (3) BG66130B1 (nl)
BR (1) BRPI0111591B8 (nl)
CA (1) CA2407659C (nl)
CY (2) CY1107710T1 (nl)
CZ (2) CZ305279B6 (nl)
DE (3) DE60128494T2 (nl)
DK (3) DK1524272T3 (nl)
ES (3) ES2288724T3 (nl)
FR (1) FR19C1044I2 (nl)
HK (1) HK1054224A1 (nl)
HU (1) HU229233B1 (nl)
IL (2) IL153067A0 (nl)
MX (1) MXPA02011899A (nl)
NL (1) NL300999I2 (nl)
NO (1) NO323873B1 (nl)
NZ (1) NZ522280A (nl)
PL (1) PL216676B1 (nl)
PT (2) PT1524272E (nl)
RU (1) RU2270198C2 (nl)
SK (1) SK287169B6 (nl)
TW (2) TWI305529B (nl)
WO (1) WO2001096300A1 (nl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128494T2 (de) * 2000-06-13 2008-01-17 Zentaris Gmbh Verbindungen zur Stimulation der Sekretion von Wachstumshormonen
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7034050B2 (en) * 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
CA2616396C (en) * 2005-07-22 2013-07-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) * 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US8431642B2 (en) * 2008-06-09 2013-04-30 Exxonmobil Chemical Patents Inc. Polyolefin adhesive compositions and articles made therefrom
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8747922B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods and compositions for increasing sex steroids and growth hormones
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US10300101B2 (en) 2012-09-19 2019-05-28 Quality IP Holdings, LLC Methods and compositions for enhancing or maintaining fertility
US8747923B2 (en) 2012-09-20 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in canines
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
US10292957B2 (en) 2012-09-20 2019-05-21 Quality IP Holdings, LLC Compositions and methods for treating fibromyalgia
US20150265680A1 (en) 2012-10-24 2015-09-24 Daiichi Sankyo Company, Limited Therapeutic agent for amyotrophic lateral sclerosis
CN105330720A (zh) * 2014-06-06 2016-02-17 深圳翰宇药业股份有限公司 一种制备马昔瑞林的方法
JP6816149B2 (ja) 2015-09-21 2021-01-20 アンモネット ファーマ エルエルシーＡｍｍｏｎｅｔｔ Ｐｈａｒｍａ ＬＬＣ 成長ホルモン欠乏症の検出および治療
US10894072B2 (en) 2017-02-13 2021-01-19 IP Quality Holdings, LLC Compositions and methods for treating fibromyalgia
US10288629B1 (en) 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
WO2022017599A1 (en) 2020-07-22 2022-01-27 Aeterna Zentaris Gmbh A screening method for diagnosing growth hormone deficiency in pediatric patients by using macimorelin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637316B2 (en) * 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
DE60128494T2 (de) * 2000-06-13 2008-01-17 Zentaris Gmbh Verbindungen zur Stimulation der Sekretion von Wachstumshormonen

Also Published As

Publication number Publication date
BG110771A (bg) 2011-03-31
PL363081A1 (en) 2004-11-15
DK1344773T3 (da) 2007-12-27
JP2003335752A (ja) 2003-11-28
JP3522265B2 (ja) 2004-04-26
CA2407659C (en) 2010-11-09
IL153067A (en) 2010-05-31
DE60130025D1 (de) 2007-09-27
ES2292900T3 (es) 2008-03-16
DK1289951T3 (da) 2005-12-19
PT1344773E (pt) 2007-11-27
PL216676B1 (pl) 2014-05-30
NO323873B1 (no) 2007-07-16
HUP0302026A2 (hu) 2003-09-29
BR0111591A (pt) 2003-05-06
US20020165343A1 (en) 2002-11-07
CY1107710T1 (el) 2013-04-18
BG66130B1 (bg) 2011-06-30
BG107379A (bg) 2003-09-30
EP1289951B1 (en) 2005-08-17
HU229233B1 (en) 2013-09-30
MXPA02011899A (es) 2003-04-22
FR19C1044I2 (fr) 2020-07-24
CA2407659A1 (en) 2001-12-20
NO20025893L (no) 2003-02-10
AU6606601A (en) 2001-12-24
RU2270198C2 (ru) 2006-02-20
CN1232507C (zh) 2005-12-21
TW200831076A (en) 2008-08-01
DE60112753D1 (de) 2005-09-22
DK1524272T3 (da) 2007-09-03
TWI305529B (en) 2009-01-21
NL300999I1 (nl) 2019-07-17
ES2288724T3 (es) 2008-01-16
DE60128494T2 (de) 2008-01-17
DE60112753T2 (de) 2006-06-29
WO2001096300A1 (en) 2001-12-20
KR20030007889A (ko) 2003-01-23
CY1107793T1 (el) 2013-06-19
BR0111591B1 (pt) 2014-02-04
CZ305279B6 (cs) 2015-07-15
DE60130025T2 (de) 2008-05-15
HK1054224A1 (en) 2003-11-21
IL153067A0 (en) 2003-06-24
HUP0302026A3 (en) 2009-01-28
AU2001266066B2 (en) 2005-06-30
NZ522280A (en) 2004-09-24
EP1289951A1 (en) 2003-03-12
SK287169B6 (sk) 2010-02-08
ATE302181T1 (de) 2005-09-15
US20040229823A1 (en) 2004-11-18
CZ20024095A3 (cs) 2003-05-14
BG110708A (en) 2010-12-30
BG66217B1 (bg) 2012-05-31
DE60128494D1 (de) 2007-06-28
SK17562002A3 (sk) 2003-05-02
NO20025893D0 (no) 2002-12-09
AR029941A1 (es) 2003-07-23
ATE362472T1 (de) 2007-06-15
ATE370119T1 (de) 2007-09-15
CZ303173B6 (cs) 2012-05-16
FR19C1044I1 (nl) 2019-09-08
ES2250416T3 (es) 2006-04-16
KR100825109B1 (ko) 2008-04-25
BRPI0111591B8 (pt) 2021-05-25
JP2004503536A (ja) 2004-02-05
US6861409B2 (en) 2005-03-01
US7297681B2 (en) 2007-11-20
JP4932132B2 (ja) 2012-05-16
BG66216B1 (bg) 2012-05-31
PT1524272E (pt) 2007-07-25
CN1431998A (zh) 2003-07-23

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
DE50106867D1 (de) Kugelgelenk
ATA2932001A (de) Schneefräse
DE60130025D1 (de) Wachstumhormonsekretionsförderer
DE50102988D1 (de) Bodenwischer
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
DE50104651D1 (de) Fahrzeugfaltverdeck
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE50007634D1 (de) Kardioplegieballonkatheter
DE10195909T1 (de) Viehfüttervorrichtung
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung